The purpose of this study is to compare effectiveness and safety of a sublingual misoprostol 12,5 mcg with vaginal misoprostol 25 mcg for induction of labour with an alive and term fetus.
Several methods for induction of labour are available. However, the most effective and with less frequency of adverse effects is still unknown. Vaginal misoprostol has been used frequently to induce labour but other routes of administrations have been proposed, such as oral and sublingual. The purpose of this study is to compare effectiveness and safety of sublingual misoprostol 12,5 mcg with vaginal misoprostol 25 mcg administration for induction of labour with an alive and term fetus. A randomized controlled double-blind trial will be carried in two hospitals: Instituto de Medicina Integral Prof. Fernando Figueira and Universidade Federal do Ceará and Instituto de Saúde Elpídio de Almeida, from July 2014 to November 2016. A total of 150 patients must be enrolled. Inclusion criteria are: a) indication for labour induction; b) term pregnancy with alive fetus; Bishop score less than six. Exclusion criteria are: a) previous uterine scar; b) nonvertex presentation; c) non-reassuring fetal status; d) fetal anomalies; e) fetal growth restriction; f) genital bleeding; g) tumors, malformations and/or ulcers of vulva, perineum or vagina. They will be randomized to receive a sublingual misoprostol 12,5 mcg with vaginal placebo tablet or sublingual placebo with vaginal misoprostol 25 mcg tablet. Vaginal tablets will have 25mcg of misoprostol or placebo. Sublingual tablet will have 12,5mcg or placebo. Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Primary outcome will be the frequency of tachysystole. Secondary outcomes will be vaginal delivery within 24 hours, hyperstimulation syndrome, cesarean section, severe neonatal morbidity or perinatal death, serious maternal morbidity or maternal death, need of oxytocin for augmentation of labour, number of misoprostol doses needed to bring on labour, interval from first dose to labour and first dose to delivery, failed induction, uterine rupture, need of labour analgesia, instrumental delivery, side effects, maternal death, meconium, non-reassuring fetal heart rate, Apgar scores less than seven at 1st and 5th minutes, admission at neonatal intensive care unit, neonatal encephalopaty, perinatal death and women not satisfied.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
150
Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
Instituto de Medicina Integral Professor Fernando Figueira (IMIP)
Recife, Pernambuco, Brazil
Frequency of taquissistoly
during 48 hours the presence of taquissistoly will be observed
Time frame: 48 hours
Hyperstimulation Syndrome
during 48 hours the presence of hyperstimulation syndrome will be observed
Time frame: 48 hours
changes in the cervix at 12 and 24 hours
changes in the cervix
Time frame: 12 and 24 hours
failure to achieve vaginal delivery within 12 and 24 hours
failure to achieve vaginal delivery
Time frame: 12 and 24 hours
the mother's preferred route of administration
Ask to mother what route of administratios was the best for her
Time frame: after 48 hours
time between the first dose and the onset of labour and delivery
to avaluete the time between the first dose and the onset of labour and delivery
Time frame: after 48 hours
duration of labour
to avaluete the time of duration of labour
Time frame: after 48 hours
need for oxytocin
to avaluete the use of oxytocin during the labour
Time frame: after 48 hours
failed induction of labour
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
to avaluete the faliled induction of labor
Time frame: after 48 hours
Caesarean section and the indications for this procedure
to avaluete the number of Caesarean section and the indications for this procedure
Time frame: after 48 hours
need for epidural anaesthesia
to avaluete the need for epidural anaesthesia
Time frame: after 48 hours
maternal side effects (nausea, vomiting, diarrhoea, postpartum haemorrhage and fever);
to avaluete if occurred any case of maternal side effects (nausea, vomiting, diarrhoea, postpartum haemorrhage and fever);
Time frame: after 48 hours
severe maternal morbidity (uterine rupture, sepsis and admission to intensive care unit) or maternal death
to avaluete severe maternal morbidity (uterine rupture, sepsis and admission to intensive care unit) or maternal death
Time frame: 48 hours
meconium in the amniotic fluid
to avaluete meconium in the amniotic fluid
Time frame: 48 hours
non-reassuring foetal heart rate
non-reassuring foetal heart rate
Time frame: 48 hours
one- and five-minute Apgar scores <7
to avaluete one- and five-minute Apgar scores \<7
Time frame: after 48 hours
admission of the newborn to a neonatal intensive care unit
to avaluete admission of the newborn to a neonatal intensive care unit
Time frame: after 48 hours
need for neonatal resuscitation
to avaluete the need for neonatal resuscitation
Time frame: after 48 hours
severe neonatal morbidity (convulsions and neonatal asphyxiation) or perinatal death.
to avaluete severe neonatal morbidity (convulsions and neonatal asphyxiation) or perinatal death.
Time frame: after 48 hours